:
R. Zweiker has relationships with following drug companies: Novartis, Servier, AstraZeneca, DaiichiSankyo, Amgen, Merck, Gebro, Sanofi, Boehringer, Abbott, Bayer and Menarini. These relationships include research grants, membership of scientific advisory boards, lecture activities and congress invitations. I. Lang has relationships with drug companies including AOPOrphan Pharmaceuticals, Actelion, Bayer-Schering, Astra-Zeneca, Menarini, Servier, Cordis, Medtronic, GSK, and Ferrer. In addition, to being investigator in trials involving these companies, I. Lang’s relationships include consultancy service, research grants, and membership of scientific advisory boards. I. Lang had access to all study data and analyses, was involved in interpretation of data; writing of the paper and decision to submit for publication. I. Lang serves on the editorial board of the European Heart Journal, Thrombosis and Haemostasis, and Pulmonary Circulation. I. Lang is not sitting on a committee or organization that may benefit from publication of this paper. E. Wallner is employee of A. Menarini Pharma GmbH Austria. G. Delle-Karth has relationships with following drug companies: Astra Zeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi-Sankyo MSD, Pfizer, Sanofi, and Menarini. These relationships include research grants, membership of scientific advisory boards, lecture activities and congress invitations. J. Aichinger and B. Metzler declare that they have no competing interests.